Stage 1 breast cancer is highly treatable, with a five-year relative survival rate of 100% for localized disease. Treatment typically involves surgery as the first step, followed by some combination of radiation, hormone therapy, targeted therapy, or chemotherapy depending on the tumor’s specific biology. Most people with stage 1 breast cancer will not need chemotherapy, but the full treatment plan can still span months to years when hormone therapy is included.
What Stage 1 Means
In stage 1 breast cancer, the tumor is 20 millimeters (about three-quarters of an inch) or smaller. It’s divided into two substages. In stage 1A, cancer is confined to the breast with no spread to lymph nodes. In stage 1B, tiny clusters of cancer cells (no larger than 2 millimeters) may be present in nearby lymph nodes, but the tumor in the breast itself is very small or may not be detectable at all.
Because the cancer is caught early and hasn’t traveled to distant parts of the body, the treatment goal is curative. Nearly two-thirds of all breast cancers are diagnosed at this localized stage.
Surgery: Lumpectomy vs. Mastectomy
Surgery is usually the first treatment. The two main options are lumpectomy (removing the tumor and a margin of surrounding tissue while keeping the rest of the breast) and mastectomy (removing the entire breast), with or without breast reconstruction. For stage 1 disease, lumpectomy followed by radiation produces long-term survival rates equivalent to mastectomy. The choice often comes down to tumor location, breast size relative to the tumor, personal preference, and genetic risk factors.
During surgery, your surgeon will also check whether cancer has reached the lymph nodes under your arm through a procedure called a sentinel lymph node biopsy. A small amount of radioactive solution, blue dye, or both is injected near the tumor before or during the operation. These tracers travel through the lymphatic system to the first few nodes that drain the tumor area. The surgeon removes those nodes, typically just a few, and sends them to a lab for examination. If the sentinel nodes are cancer-free, no further lymph node surgery is needed. This approach is far less invasive than removing a large number of lymph nodes and carries a lower risk of arm swelling afterward.
Radiation After Lumpectomy
If you have a lumpectomy, radiation therapy to the breast follows surgery to destroy any remaining cancer cells and reduce the chance of recurrence. The standard course has traditionally been whole-breast radiation given five days a week for three to five weeks, sometimes followed by an additional “boost” of radiation to the specific area where the tumor was removed, lasting another four to eight days.
More recently, a shorter three-week course (called hypofractionated radiation) has been shown to be equally safe and effective for many people with early-stage breast cancer. In this approach, the boost doses can be delivered during the same three-week period rather than tacked on afterward, cutting total treatment time significantly. Your radiation oncologist will recommend the schedule that fits your situation, but the trend in early-stage breast cancer is clearly toward shorter courses. If you have a mastectomy for stage 1 disease, radiation is generally not needed unless there are specific risk factors.
Hormone Therapy for ER-Positive Tumors
About 70 to 80 percent of breast cancers are hormone receptor-positive, meaning they grow in response to estrogen or progesterone. If your tumor falls into this category, you’ll be recommended hormone therapy (also called endocrine therapy) after surgery. This is typically the longest part of treatment, lasting a minimum of five years.
The specific medication depends on whether you’ve gone through menopause. Postmenopausal women are generally prescribed an aromatase inhibitor, which blocks the body’s production of estrogen. Premenopausal women typically take tamoxifen, which blocks estrogen from binding to cancer cells. For younger women with higher-risk features, tamoxifen may be combined with ovarian function suppression to further lower estrogen levels.
Five years of hormone therapy cuts recurrence risk by roughly 50% and reduces mortality by about one-third. For stage 1 patients with low to intermediate risk and no or minimal lymph node involvement, five to seven years is considered the optimal duration. Women with additional risk factors may be advised to continue for up to ten years. These medications are taken as a daily pill, and while they’re effective, they can cause side effects like hot flashes, joint stiffness, and fatigue that are worth discussing with your oncologist so you can manage them over the long haul.
When Chemotherapy Is Recommended
Many people with stage 1 breast cancer do not need chemotherapy, but the decision depends on the tumor’s biology. For hormone receptor-positive, HER2-negative tumors, a genomic test called Oncotype DX is commonly used to guide this decision. The test analyzes genes within the tumor and assigns a recurrence score from 0 to 100.
A score of 0 to 10 is considered low risk, and hormone therapy alone after surgery is sufficient. A score of 26 or above indicates a clear benefit from adding chemotherapy to hormone therapy. The middle range, 11 to 25, is where the decision gets more nuanced. A large clinical trial called TAILORx found that most women in this intermediate range did just as well with hormone therapy alone, though younger premenopausal women with scores on the higher end of that range may still benefit from chemotherapy. This test has spared a significant number of early-stage patients from unnecessary chemotherapy and its side effects.
Targeted Therapy for HER2-Positive Cancers
About 15 to 20 percent of breast cancers produce excess amounts of a protein called HER2, which fuels tumor growth. If your stage 1 cancer is HER2-positive, targeted therapy with trastuzumab is a standard part of treatment. Trastuzumab is an antibody that latches onto the HER2 protein and blocks it from signaling the cancer to grow. It’s given alongside chemotherapy and continued for a total of one year after surgery.
In some cases, a second targeted drug called pertuzumab is added to trastuzumab for a stronger effect. If the cancer doesn’t respond completely to treatment given before surgery (called neoadjuvant therapy), a different drug may be recommended to reduce recurrence risk. The addition of HER2-targeted therapies has dramatically improved outcomes for this historically more aggressive subtype of breast cancer.
The Overall Treatment Timeline
From diagnosis to the end of active treatment (not counting long-term hormone therapy), the process generally spans several months. Surgery comes first, usually scheduled within a few weeks of diagnosis, giving you time to get second opinions or explore options. Recovery from lumpectomy takes one to two weeks for most people; mastectomy recovery is longer, particularly with reconstruction.
If radiation is needed, it begins a few weeks after surgery and lasts three to six weeks. Chemotherapy, when indicated, is typically given either before surgery (neoadjuvant) or after (adjuvant) and runs for several months. HER2-targeted therapy spans a full year. Hormone therapy then continues for five years or more as a daily pill, well after other treatments have ended. The intensity of treatment front-loads in the first several months, then settles into the quieter but important long-term phase of hormone therapy and regular follow-up imaging.